B lymphocyte-typing for prediction of clinical response to rituximab

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Brezinschek, Hans Peter ^a   Rainer, Franz ^b   Brickmann, Kerstin ^a   Graninger, Winfried B ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TYPING; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BLOOD; COHORT ANALYSIS; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; REGISTER; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGISTRIES; TREATMENT OUTCOME;

EID: 84863438982     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3901     Document Type: Article

References (29)

1. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dorner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011, 70(Suppl 1):i2-36. 10.1136/ard.2010.146852, 21339216.
2. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011, 13(Suppl 1):S5. 3123966, 21624184.
3. Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007, 47:1119-1128. 10.1177/0091270007305297, 17766699.
4. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008, 58:2993-2999. 10.1002/art.23902, 18821683.
5. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, Ponchel F, Emery P. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010, 62:1273-1279. 10.1002/art.27359, 20131284.
6. Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, McGonagle D. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011, 63:603-608. 10.1002/art.30152, 21360489.
7. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54:2377-2386. 10.1002/art.22019, 16869000.
8. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009, 11:R123. 10.1186/ar2789, 2745807, 19686595.
9. Moller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vogelin E, Ziswiler HR, Dahinden CA, Villiger PM. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R62. 10.1186/ar2686, 2714106, 19419560.
10. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005, 105:4390-4398. 10.1182/blood-2004-11-4284, 1895038, 15701725.
11. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009, 45:144-158.
12. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008, 20:67-82. 10.1016/j.smim.2007.12.006, 2440717, 18258454.
13. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester GR, Diamond B, Lipsky PE, Dorner T. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008, 58:1762-1773. 10.1002/art.23498, 18512812.
14. Rau FC, Dieter J, Luo Z, Priest SO, Baumgarth N. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J Immunol 2009, 183:7661-7671. 10.4049/jimmunol.0803783, 2795108, 19933871.
15. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
16. Avery DT, Ellyard JI, Mackay F, Corcoran LM, Hodgkin PD, Tangye SG. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J Immunol 2005, 174:4034-4042.
17. Shubinsky G, Schlesinger M. The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. Immunity 1997, 7:315-324. 10.1016/S1074-7613(00)80353-2, 9324352.
18. Buffa S, Bulati M, Pellicano M, Dunn-Walters DK, Wu YC, Candore G, Vitello S, Caruso C, Colonna-Romano G. B cell immunosenescence: different features of naive and memory B cells in elderly. Biogerontology 2011, 12:473-483. 10.1007/s10522-011-9353-4, 21879287.
19. Lagresle C, Bella C, Defrance T. Phenotypic and functional heterogeneity of the IgD- B cell compartment: identification of two major tonsillar B cell subsets. Int Immunol 1993, 5:1259-1268. 10.1093/intimm/5.10.1259, 7505610.
20. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 1994, 180:329-339. 10.1084/jem.180.1.329, 2191579, 8006591.
21. Mei HE, Yoshida T, Muehlinghaus G, Hiepe F, Dorner T, Radbruch A, Hoyer BF. Phenotypic analysis of B-cells and plasma cells. Methods Mol Med 2007, 136:3-18. 10.1007/978-1-59745-402-5_1, 17983136.
22. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Ezendam NP, Levarht EW, Breedveld FC, Verweij CL. Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis. Arthritis Rheum 2001, 44:2029-2037. 10.1002/1529-0131(200109)44:9<2029::AID-ART352>3.0.CO;2-2, 11592364.
23. Snapper CM, Rosas FR, Zelazowski P, Moorman MA, Kehry MR, Bravo R, Weih F. B cells lacking RelB are defective in proliferative responses, but undergo normal B cell maturation to Ig secretion and Ig class switching. J Exp Med 1996, 184:1537-1541. 10.1084/jem.184.4.1537, 2192806, 8879226.
24. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009, 11:R84. 10.1186/ar2718, 2714135, 19500335.
25. Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, Rodriguez C, Brieva JA. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther 2010, 12:R108. 10.1186/ar3042, 2911899, 20525218.
26. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000, 1:469-474. 10.1038/82712, 11101867.
27. Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:26-30.
28. Rodriguez-Bayona B, Perez-Venegas JJ, Rodriguez C, Brieva JA. CD95-Mediated control of anti-citrullinated protein/peptides antibodies (ACPA)-producing plasma cells occurring in rheumatoid arthritis inflamed joints. Rheumatology (Oxford) 2007, 46:612-616.
29. Agematsu K, Nagumo H, Oguchi Y, Nakazawa T, Fukushima K, Yasui K, Ito S, Kobata T, Morimoto C, Komiyama A. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 1998, 91:173-180.